normal
myeloid
cell
monocyt
granulocyt
origin
express
metallopeptidas
cluster
differenti
surfac
leukem
blast
acut
myeloid
leukemia
aml
minor
percentag
aml
patient
howev
lack
surfac
express
antigen
studi
differ
surfac
express
specif
mrna
individu
quantifi
competit
revers
transcript
polymeras
chain
reaction
rtpcr
absolut
valu
transcript
normalis
dehydrogenas
gapdh
transcript
level
control
variat
sampl
prepar
mrna
degrad
correl
normalis
transcript
level
surfac
express
subgroup
aml
patient
identifi
simultan
diminish
level
myeloid
transcript
surfac
express
correspond
antigen
subgroup
suggest
n
apn
gene
express
restrict
primarili
limit
amount
transcript
major
aml
patient
determin
addit
transcript
level
must
involv
regul
gene
express
glycoprotein
cluster
differenti
structur
ident
aminopeptidas
n
apn
within
hematopoiet
system
antigen
express
surfac
earli
commit
progenitor
granulocyt
monocyt
cfugm
matur
cell
lineag
antibodi
specif
bind
normal
b
lymphocyt
outsid
hematopoiet
system
express
demonstr
cell
tissu
includ
fibroblast
bone
marrow
stroma
cell
osteoclast
endotheli
cell
intestin
epithelium
renal
tubular
epithelium
synapt
membran
central
nervou
system
within
intestin
system
catalys
remov
nh
termin
amino
acid
peptid
known
serv
receptor
coronavirus
function
locat
outsid
hematopoiet
system
known
suggest
involv
degrad
bioactiv
molecul
well
tumour
invas
matrix
degrad
recent
shown
possibl
involv
process
present
antigen
thought
specif
role
control
growth
cell
differenti
within
hematopoiet
epitheli
cell
system
leukem
blast
express
surfac
acut
myeloid
leukemia
aml
therefor
use
one
routin
marker
diagnosi
aml
sinc
neither
function
mechan
regul
lineagerestrict
express
fulli
elucid
myeloid
cell
becam
interest
compar
aml
case
surfac
posit
neg
respect
gain
insight
express
regul
aml
presenc
leukem
cell
propos
potenti
marker
predict
outcom
adult
aml
posit
case
report
enter
complet
remiss
lower
frequenc
reduc
surviv
compar
neg
case
addit
characterist
aml
patient
vari
degre
antigen
surfac
express
could
therefor
interest
studi
determin
surfac
express
transcript
level
within
mononuclear
cell
origin
aml
patient
median
blast
percent
four
healthi
control
relat
transcript
level
dehydrogenas
gapdh
transcript
level
order
normalis
content
mrna
variat
sampl
degrad
handl
observ
normalis
transcript
level
correl
surfac
express
variou
clinic
patholog
cytogenet
find
rna
extract
mononuclear
cell
aml
patient
revers
transcrib
cdna
pcr
amplifi
use
specif
primer
gapdh
pcr
product
sequenc
verifi
use
autom
cycl
sequenc
dyedeoxi
nucleotid
termin
dna
sequenc
appli
biosystem
inc
ca
usa
primer
sequenc
follow
sens
xcgagatctcgagtccagggtccaggttccag
x
denot
biotin
underlin
nucleotid
bglii
restrict
site
primer
c
fig
antisens
cgcaagcttgcgtgacagtgcgatgattgtgcac
underlin
nucleotid
denot
hindiii
restrict
site
primer
c
fig
gapdh
sens
xcggaattccggagtcaacggatttggtcg
x
denot
biotin
underlin
nucleotid
ecori
restric
tion
site
antisens
gapdh
cgcggatcccgagggatctcgctcctggaag
underlin
nucleotid
denot
bamhi
restrict
site
oligonucleotid
purchas
dna
technolog
aarhu
denmark
primer
design
span
mluni
restrict
site
wherea
gapdh
harbour
intern
ncoi
restrict
site
digest
intern
restrict
enzym
divid
pcr
product
two
fig
dynabead
fig
construct
homolog
intern
standard
pcr
amplifi
area
target
biotinyl
primer
bglii
restrict
site
primer
c
primer
hindiii
restrict
site
primer
c
amplifi
area
contain
mluni
restrict
site
mluni
digest
biotin
mediat
separ
two
fragment
follow
pcr
modif
end
respect
nonhuman
sequenc
origin
linker
sequenc
primer
complementari
linker
sequenc
primer
ligat
togeth
pcr
amplif
utilis
primer
ii
clonabl
fragment
obtain
subsequ
restrict
digest
hindiii
bglii
iii
b
localis
competit
primer
target
mrna
mrna
origin
myeloid
promot
amplifi
sinc
posit
exon
c
localis
competit
primer
mrna
nucleotid
nonhuman
origin
introduc
exogen
transcript
dynal
oslo
norway
purif
two
fragment
follow
pcr
mediat
modif
two
fragment
linker
sequenc
origin
cdna
plant
transcript
factor
pallisgaard
unpublish
manuscript
ad
end
end
two
fragment
respect
primer
follow
sens
caccgtcctgcagatcggcaaggcacaaaagaggttgcaattgcaaa
accaagggcttctatatttcc
primer
c
fig
antisens
ccgatctgcaggacggtgttgtctagattttcatcatccatatgt
gaaccatggtgatggtgggg
primer
c
fig
sens
gapdh
caccgtcccagatcggccaggcacaaaagaggttgcaacatggcaccgtcaaggctg
antisens
gapdh
ccgatctgcaggacggtgttgtctagattttcatcatccgaatttgccatgggtggaatc
underlin
nucleotid
denot
overlap
sequenc
linker
sequenc
complementari
nucleotid
could
henc
ligat
togeth
afterward
pcr
shown
fig
thu
nonhuman
sequenc
introduc
middl
target
area
gapdh
attach
dynabead
modifi
product
digest
hindiii
wherea
gapdh
product
treat
bamhi
cut
nucleotid
remov
wash
dynabead
digest
product
bglii
gapdh
ecori
ensur
pcr
fragment
found
solut
readi
ligat
alreadi
ecoribamhi
hindiiibglii
digest
clone
vitro
transcript
plasmid
promega
wi
usa
construct
plasmid
amplifi
electrotransform
e
coli
strain
due
ampicillin
gene
select
ampicillin
resist
coloni
possibl
clone
plasmid
sequenc
ensur
right
sequenc
linearis
clone
plasmid
use
templat
vitro
transcript
polymeras
follow
direct
manufactur
ambion
kit
tx
usa
synthesis
singl
strand
rna
separ
ribonucleotid
short
transcript
denatur
polyacrylamid
gel
rna
purifi
polyacrylamid
gel
phenolchloroform
extract
follow
ammoniumacet
ethanol
precipit
rna
resolv
trisedta
buffer
made
diethyl
pyrocarbon
treat
water
concentr
measur
absorpt
nm
three
dilut
rna
aliquot
store
trisedta
buffer
contain
rnasin
pharmacia
uppsala
sweden
mononuclear
cell
prepar
bone
marrow
aspir
densiti
gradient
separ
use
lymphoprep
nycom
oslo
norway
mononuclear
cell
cryopreserv
dimethylsulfoxid
fetal
calf
serum
liquid
nitrogen
prior
rna
extract
thaw
mononuclear
cell
wash
time
hbssbuffer
hank
balanc
salt
solut
gibco
brl
ny
usa
total
rna
prepar
use
procedur
guanidin
thiocyan
phenol
chloroform
genosi
kit
london
uk
rna
concentr
determin
absorpt
nm
cdna
synthesi
carri
firststrand
synthesi
kit
pharmacia
uppsala
sweden
follow
direct
manufactur
firststrand
synthesi
prime
random
hexadeoxynucleotid
primer
provid
kit
patient
seven
sampl
prepar
mg
patient
rna
serial
dilut
rna
gapdh
cover
rang
rna
molecul
volum
ml
dilut
cdna
mixtur
use
templat
pcr
amplif
pcr
perform
perkin
elmer
follow
condit
initi
min
activ
amplitaq
gold
perkin
elmerroch
ca
usa
repeat
cycl
final
last
extens
step
min
ml
pcr
u
amplitaq
gold
use
addit
mm
dntp
mm
mgcl
pmol
primer
sens
gtccagggtccaggttccag
primer
c
fig
antisens
tgacagtgcgatgattgtgcac
primer
c
fig
sens
gapdh
cggagtcaacggatttggtcg
antisens
gapdh
agggatctcgctcctggaag
competit
pcr
gapdh
perform
separ
tube
ie
seven
pcr
tube
seven
pcr
tube
gapdh
templat
cdna
use
seven
differ
dilut
step
gapdh
origin
ident
reaction
sinc
pcr
primer
gapdh
similar
temperatur
optima
pcr
amplif
gapdh
perform
simultan
fig
b
show
posit
primer
target
mrna
fig
show
posit
primer
mrna
ten
microlitr
pcr
product
load
ethidiumbromid
stain
agaros
gel
electrophoret
separ
intens
luminesc
target
band
measur
chargedcoupl
devic
ccd
camera
biorad
ca
usa
et
al
patient
inv
classifi
belong
favour
group
complex
abnorm
karyotyp
least
three
aberr
karyotyp
del
abnorm
constitut
group
associ
poor
prognosi
patient
normal
karyotyp
aberr
list
two
group
belong
intermedi
group
studi
base
bone
marrow
aspir
aml
patient
four
healthi
control
diagnosi
aml
base
fab
criteria
immunophenotyp
cytogenet
time
diagnosi
median
age
year
sampl
femal
male
analys
patient
primari
aml
one
secondari
aml
two
aml
develop
myelodysplast
syndrom
two
patient
remiss
tabl
summaris
affect
clinic
paramet
one
patient
enlarg
spleen
liver
lymph
node
anoth
patient
enlarg
spleen
lymph
node
third
enlarg
liver
lymph
node
thu
nine
patient
clinic
implic
identif
fab
subtyp
base
morpholog
cytochem
analysi
order
test
whether
amplif
effici
gapdh
ident
gapdh
target
respect
pcr
perform
use
cdna
contain
target
equival
concentr
pcr
cycl
amplifi
product
analys
electrophoresi
band
intens
measur
due
differ
size
target
band
intens
correct
calcul
ratio
target
gapdh
ratio
shown
constant
rang
pcr
cycl
fig
addit
experi
show
plateau
target
alik
sinc
accumul
pcr
product
increas
cycl
number
data
shown
amplif
effici
ident
target
graphic
represent
logarithm
histarget
logarithm
initi
amount
linear
curv
gapdh
histarget
ratio
linear
within
dilut
rang
target
pcr
amplifi
data
shown
howev
either
target
present
larg
excess
one
product
amplifi
densiometr
analysi
identifi
dilut
step
competit
pcr
ratio
target
shift
patient
competit
pcr
perform
replica
use
cdna
correspond
three
four
dilut
step
surround
equival
point
order
ensur
reproduc
quantif
calcul
ratio
target
regress
analysi
made
initi
amount
target
within
sampl
found
relat
gapdh
level
within
sampl
purifi
mononuclear
cell
bone
marrow
aml
patient
analys
coulter
profileor
coulter
epic
flow
cytometri
instrument
coulter
luton
uk
use
forwardligthscatt
gate
least
cell
analys
use
log
amplif
mode
neg
control
mononuclear
cell
label
second
antibodi
layer
alon
previous
describ
gate
made
exclud
debri
cell
fragment
percentag
report
percent
posit
total
mononuclear
cell
number
median
blast
percent
analys
aml
rang
monoclon
antibodi
use
identifi
surfac
fluorescein
isothiocyanateconjug
coulter
immunolog
luton
uk
bone
marrow
cell
cultur
vitro
h
metaphas
chromosom
stain
wrigth
stain
therebi
visualis
giemsa
band
karyotyp
sort
three
prognost
group
accord
criteria
laid
grimwad
sinc
effici
cdna
synthesi
pcr
may
constant
estim
reproduc
competit
rtpcr
assay
perform
analysi
show
convers
rna
detect
pcr
product
may
introduc
fold
variat
determin
initi
amount
gapdh
transcript
confid
limit
sensit
competit
rtpcr
test
mix
variou
amount
posit
promyelocyt
leukem
cell
neg
acut
lymphoblast
preb
cell
mix
ratio
confirm
flow
cytometri
detect
pcr
product
dilut
step
correspond
rna
molecul
easili
observ
cell
wherea
target
amplifi
use
mrna
origin
neg
cell
data
shown
sinc
flow
cytometri
reliabl
defin
lesser
percentag
replica
two
analys
investig
mix
ratio
cell
mix
cell
transcript
correspond
transcript
detect
fig
ratio
standard
target
around
equival
point
transcript
linear
indic
reliabl
quantif
data
shown
thu
transcript
could
identifi
still
within
linear
rang
method
adjust
differ
sampl
prepar
rna
degrad
amount
transcript
normalis
gapdh
transcript
amount
within
sampl
gapdh
housekeep
gene
other
use
normalis
fig
c
show
gapdh
transcript
level
independ
express
surfac
quantifi
mrna
origin
myeloid
promot
sinc
upstream
primer
locat
exon
seen
fig
exon
structur
sequenc
defin
shapiro
et
al
thu
altern
transcript
initi
intestin
promot
includ
normalis
transcript
level
determin
occurr
pcr
product
low
dilut
rang
origin
dna
contamin
rna
sinc
direct
pcr
perform
rna
prepar
result
amplif
data
shown
mononuclear
cell
bone
marrow
aspir
aml
patient
four
healthi
control
analys
competit
rtpcr
content
gapdh
transcript
determin
result
normalis
transcript
level
among
patient
vari
thu
cover
rang
fold
healthi
control
valu
variat
among
less
four
fold
distribut
normalis
transcript
shown
fig
normalis
transcript
level
fell
two
group
aml
patient
intermedi
high
valu
wherea
low
valu
sinc
averag
content
gapdh
transcript
major
patient
respect
correspond
valu
remain
eight
patient
small
group
characteris
high
valu
gapdh
lower
valu
intens
surfac
antigen
regist
averag
fluoresc
divid
three
logarithm
decad
defin
low
intermedi
high
fluoresc
sinc
analys
perform
flow
cytomet
regularli
test
trim
avoid
day
day
variat
comparison
antigen
intens
aml
patient
possibl
sampl
analys
low
ten
intermedi
antigen
intens
patient
high
low
low
averag
fluoresc
surfac
intens
observ
concentr
mononuclear
cell
therefor
consid
compar
ten
patient
high
eight
patient
low
ten
patient
intermedi
antigen
intens
seven
surfac
express
antigen
mononuclear
cell
data
shown
thu
patient
high
percentag
posit
mononuclear
cell
may
slightli
increas
concentr
antigen
cellular
surfac
howev
none
ten
patient
intermedi
antigen
intens
significantli
increas
normalis
transcript
level
compar
remain
patient
shown
fig
myeloid
differenti
express
pattern
myeloid
cd
marker
gradual
chang
matur
myeloid
cell
aml
patient
judg
immunophenotyp
hladr
express
surfac
antigen
averag
patient
low
averag
high
averag
tabl
similar
pattern
observ
antigen
averag
patient
low
high
averag
valu
respect
hladr
found
mononuclear
cell
averag
patient
low
averag
high
averag
thu
low
compar
high
similar
express
rate
myeloid
immatur
marker
hladr
well
matur
marker
time
diagnosi
chromosom
studi
carri
patient
karyotyp
group
three
prognost
group
defin
grimwad
et
al
see
section
none
patient
belong
prognost
favour
group
three
complex
abnorm
karyotyp
associ
remain
belong
intermedi
group
nineteen
present
normal
karyotyp
seven
cytogenet
analys
patient
low
intermedi
prognos
tabl
mononuclear
cell
analys
flow
cytometri
express
myeloid
antigen
surfac
determin
done
patient
sampl
use
determin
normalis
transcript
level
competit
rtpcr
flow
cytometri
carri
prior
cryopreserv
relat
cell
surfac
express
normalis
transcript
shown
fig
aml
patient
four
healthi
control
intermedi
high
valu
normalis
transcript
level
linear
correl
normalis
transcript
level
cell
surfac
express
r
p
b
n
correl
howev
ambigu
sinc
r
r
measur
proport
explain
varianc
surfac
express
explain
variat
normalis
transcript
limit
correl
also
reflect
similar
transcript
level
mediat
surfac
express
differ
posit
mononuclear
cell
similar
transcript
level
result
posit
mononuclear
cell
shown
fig
healthi
control
higher
normalis
transcript
level
patient
similar
surfac
express
ten
patient
surfac
express
intermedi
high
normalis
transcript
level
defin
high
patient
low
normalis
transcript
level
anoth
pattern
emerg
eight
patient
simultan
low
valu
normalis
transcript
low
express
antigen
surfac
mononuclear
cell
none
myeloid
antigen
cell
surfac
defin
low
patient
high
compar
distribut
observ
intermedi
prognos
one
poor
prognosi
one
cytogenet
examin
classif
patient
fab
categori
summaris
tabl
whole
rang
observ
normalis
transcript
level
includ
low
high
obviou
correl
fab
classif
found
aml
patient
median
age
diagnosi
year
four
still
aliv
year
diagnosi
two
aliv
year
one
aliv
year
diagnosi
patient
dead
surviv
analysi
use
censor
date
overal
averag
surviv
day
day
die
low
patient
median
age
time
diagnosi
year
averag
surviv
day
tabl
day
diagnosi
still
aliv
high
patient
median
age
diagnosi
year
averag
surviv
day
day
diagnosi
aliv
one
survivor
found
within
high
none
patient
low
still
aliv
thu
low
patient
tend
surviv
longer
high
patient
differ
statist
signific
order
leav
age
diagnosi
account
compar
surviv
low
high
seven
patient
highest
normalis
transcript
level
median
age
year
compar
five
patient
lowest
normalis
transcript
level
median
age
year
therebi
differ
surviv
rate
becam
pronounc
sinc
seven
high
patient
surviv
day
averag
five
low
patient
surviv
day
p
seven
high
five
low
compar
distribut
regard
prognost
group
regard
spleen
liver
enlarg
lymph
tumour
skin
infiltr
complic
restrict
particular
group
patient
found
randomli
among
averag
concentr
leukocyt
patient
l
high
l
low
l
leukocyt
thrombocyt
concentr
averag
patient
l
wherea
high
low
contain
l
l
respect
haemoglobin
content
mmoll
averag
patient
mmol
high
low
thu
connect
normalis
transcript
leukocyt
thrombocyt
haemoglobin
found
depart
de
novo
aml
patient
surfac
express
less
mononuclear
cell
bone
marrow
achiev
better
understand
certain
aml
patient
lack
myeloid
antigen
determin
normalis
cd
transcript
level
perform
cryopreserv
materi
valu
normalis
transcript
fell
two
group
major
aml
patient
intermedi
high
level
low
level
four
healthi
control
high
transcript
level
compar
aml
patient
similar
surfac
express
heterogen
natur
bone
marrow
cell
could
offer
explan
sinc
observ
specif
mrna
present
human
cell
line
without
simultan
express
antigen
surfac
aml
patient
less
surfac
express
mononuclear
cell
enhanc
divers
normalis
transcript
level
observ
patient
low
high
respect
normalis
transcript
level
differ
express
respect
mononuclear
cell
differ
variat
normalis
transcript
level
found
aml
patient
less
surfac
express
antigen
patient
cd
surfac
antigen
express
variat
normalis
transcript
level
ten
fold
surfac
express
alik
variat
normalis
transcript
level
within
low
high
similar
rang
fold
sinc
bone
marrow
cell
median
blast
count
high
low
respect
lymphocyt
constitut
mononuclear
cell
group
differ
normalis
transcript
level
caus
differ
composit
analys
cell
popul
thu
high
enrich
lymphocyt
intracellular
mrna
lack
surfac
express
antigen
divers
normalis
transcript
level
found
patient
less
antigen
surfac
mononuclear
cell
caus
limit
competit
rtpcr
method
theoret
demand
method
empir
test
satisfactori
result
henc
target
similar
amplif
effici
concentr
templat
close
graphic
present
logarithm
histarget
linear
within
dilut
rang
target
amplifi
ratio
target
other
report
import
obtain
reliabl
quantif
show
ratio
target
close
amplif
effici
similar
competit
rtpcr
method
result
linear
relat
present
studi
quantif
perform
data
within
rang
similar
amplif
effici
obtain
even
though
length
target
vari
base
pair
base
pair
gapdh
accord
observ
made
other
show
amplif
effici
unaffect
differ
length
much
bp
target
endogen
standard
gapdh
necessari
control
variat
sampl
prepar
mrna
degrad
other
use
gapdh
intern
control
pcr
quantif
howev
ensur
gapdh
gene
express
systemat
underor
stimul
aml
patient
increas
surfac
express
antigen
comparison
gapdh
mrna
level
rel
surfac
express
perform
seen
fig
c
influenc
indic
furthermor
correl
observ
gapdh
mrna
level
mrna
level
data
shown
sensit
competit
rtpcr
method
test
mix
cell
line
materi
posit
neg
surfac
express
sinc
mrna
origin
ten
posit
cell
easili
detect
pool
neg
cell
sensit
assay
determin
order
magnitud
other
report
reproduc
competit
pcr
rang
two
ten
fold
thu
reproduc
approxim
two
fold
consid
accept
depend
tissu
type
transcript
apn
gene
origin
two
differ
promot
leukem
bcell
surfac
express
suggest
promotermedi
regul
sinc
stroma
cell
suppr
transcript
gene
accordingli
studi
activationdepend
induct
tcell
result
suggest
gene
express
regul
transcript
level
affect
promot
activ
well
posttranscript
level
affect
stabilis
mrna
post
transcript
event
affect
mrna
condit
also
observ
rat
frontal
cortex
promot
mediat
regul
surfac
express
shown
depend
promot
activ
endometri
cell
henc
regul
gene
express
complex
includ
sever
point
suscept
influenc
present
studi
analys
perform
limit
amount
cryopreserv
patient
materi
allow
gene
regul
investig
therefor
substanti
conclus
mechan
control
gene
express
could
made
howev
observ
normalis
transcript
level
surfac
express
lend
support
consider
regul
gene
express
simultan
low
level
normalis
transcript
surfac
express
observ
low
whatev
caus
lack
transcriptwheth
due
suppress
transcript
degrad
mrnait
suggest
amount
transcript
import
determin
low
surfac
antigen
express
within
specif
aml
patient
remain
aml
patient
addit
factor
must
involv
support
statist
r
observ
normalis
transcript
intermedi
high
level
transcript
within
high
mediat
increas
surfac
antigen
express
compar
low
patient
similar
transcript
level
differ
level
surfac
express
sinc
mononuclear
cell
immunophenotyp
examin
nonecelladher
circul
isoform
may
present
aml
patient
intermedi
high
level
normalis
transcript
divis
aml
patient
less
mononuclear
cell
low
high
base
distribut
normalis
transcript
level
among
includ
aml
patient
conceiv
valu
distinctli
separ
case
gradual
transit
exist
low
level
normalis
high
level
normalis
transcript
divis
low
high
made
enabl
judgement
possibl
correl
transcript
level
paramet
two
group
similar
regard
myeloid
matur
cell
judg
immunophenotyp
hladr
chromosom
abnorm
known
import
prognost
factor
compar
individu
low
transcript
level
less
surfac
express
tendenc
surviv
longer
patient
high
transcript
level
howev
number
patient
includ
studi
small
justifi
statist
analysi
one
might
specul
whether
low
good
risk
factor
aml
